Kelli S. Zeigler

DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY

Keith W. Ward, Gary J. Stelman, Jayme A. Morgan et al. · Drug Metabolism and Disposition · 2004 · 43 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase

Katie Ward, J. W. Proksch, L. M. Azzarano et al. · Xenobiotica · 2001 · 23 citations

Medicine, Pharmacokinetics, Pharmacology +9

2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines

Craig A. Zificsak, Jay Theroff, Lisa D. Aimone et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 17 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group

Karen L. Milkiewicz, Lisa D. Aimone, Mark S. Albom et al. · Bioorganic & Medicinal Chemistry · 2011 · 14 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14